CTOs on the Move

Sherlock Biosciences

www.sherlock.bio

 
Sherlock Biosciences aims to disrupt molecular diagnostics with better, faster, affordable tests. With our unique Engineering Biology platforms, we are on the cusp of solving challenges ranging from faster pathogen detection and simpler testing for cancer to improved food safety. We envision a world where our products will enable users to make more effective decisions in any environment, whether in hospitals, industrial settings, the developing world, or at home. Our team and founders include Engineering Biology pioneers with world-leading expertise in CRISPR and Synthetic Biology, diagnostic industry veterans, and disease-area authorities. Together, they provide an unparalleled set of capabilities that ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sherlock.bio
  • 35 Spinelli Place
    Cambridge, MA USA 02142
  • Phone: 617.702.6263

Executives

Name Title Contact Details
William Blake
Chief Technology Officer Profile

Funding

Sherlock Biosciences raised $31M on 04/23/2019
Sherlock Biosciences raised $80M on 03/08/2022

Similar Companies

healthchemdiagnostics

healthchemdiagnostics is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IFM Therapeutics

At IFM Therapeutics, LLC, we work to improve the lives of patients with inflammatory disorders and cancer by developing transformative medicines that precisely target the innate immune system, the body`s first line of immunological response and an essential component of immune function.

Elan

Elan is a biotechnology company, headquartered in Ireland, committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world.

Dow Pharmaceutical Sciences

Dow Pharmaceutical Sciences is a Petaluma, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Miragen Therapeutics

miRagen Therapeutics, Inc., is a biopharmaceutical company discovering and developing innovative microRNA (miRNA)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. From its founding, miRagen has developed ongoing, collaborative relationships with academic institutions that give the company unique access to the most promising early-stage discoveries. This access to groundbreaking science provides a significant strategic advantage in the rapidly-developing field of miRNA-targeting therapeutics.